Aytu Bioscience Stock Performance
| AYTU Stock | USD 2.63 0.02 0.75% |
Aytu BioScience holds a performance score of 11 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of -0.71, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Aytu BioScience are expected to decrease at a much lower rate. During the bear market, Aytu BioScience is likely to outperform the market. Use Aytu BioScience potential upside, as well as the relationship between the accumulation distribution and price action indicator , to analyze future returns on Aytu BioScience.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Aytu BioScience are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak basic indicators, Aytu BioScience unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 23 M | |
| Total Cashflows From Investing Activities | -329 K |
Aytu BioScience Relative Risk vs. Return Landscape
If you would invest 109.00 in Aytu BioScience on April 28, 2025 and sell it today you would earn a total of 154.00 from holding Aytu BioScience or generate 141.28% return on investment over 90 days. Aytu BioScience is currently generating 2.0304% in daily expected returns and assumes 13.3578% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Aytu, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Aytu BioScience Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Aytu BioScience's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Aytu BioScience, and traders can use it to determine the average amount a Aytu BioScience's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.152
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | AYTU | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 13.36 actual daily | 96 96% of assets are less volatile |
Expected Return
| 2.03 actual daily | 40 60% of assets have higher returns |
Risk-Adjusted Return
| 0.15 actual daily | 11 89% of assets perform better |
Based on monthly moving average Aytu BioScience is performing at about 11% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Aytu BioScience by adding it to a well-diversified portfolio.
Aytu BioScience Fundamentals Growth
Aytu Stock prices reflect investors' perceptions of the future prospects and financial health of Aytu BioScience, and Aytu BioScience fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Aytu Stock performance.
| Return On Equity | -0.0306 | ||||
| Return On Asset | -0.0059 | ||||
| Profit Margin | 0.02 % | ||||
| Operating Margin | 0.13 % | ||||
| Current Valuation | 26.81 M | ||||
| Shares Outstanding | 8.98 M | ||||
| Price To Earning | (0.77) X | ||||
| Price To Book | 0.68 X | ||||
| Price To Sales | 0.29 X | ||||
| Revenue | 81 M | ||||
| EBITDA | (1.01 M) | ||||
| Cash And Equivalents | 23.81 M | ||||
| Cash Per Share | 0.38 X | ||||
| Total Debt | 15.13 M | ||||
| Debt To Equity | 0.47 % | ||||
| Book Value Per Share | 5.66 X | ||||
| Cash Flow From Operations | (1.39 M) | ||||
| Earnings Per Share | (1.49) X | ||||
| Total Asset | 118.09 M | ||||
| Retained Earnings | (319.97 M) | ||||
| Current Asset | 6.36 M | ||||
| Current Liabilities | 8.73 M | ||||
About Aytu BioScience Performance
Assessing Aytu BioScience's fundamental ratios provides investors with valuable insights into Aytu BioScience's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Aytu BioScience is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado. Aytu Biopharma operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 164 people.Things to note about Aytu BioScience performance evaluation
Checking the ongoing alerts about Aytu BioScience for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Aytu BioScience help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Aytu BioScience is way too risky over 90 days horizon | |
| Aytu BioScience appears to be risky and price may revert if volatility continues | |
| Aytu BioScience has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 81 M. Net Loss for the year was (15.84 M) with profit before overhead, payroll, taxes, and interest of 52.89 M. | |
| Aytu BioScience currently holds about 23.81 M in cash with (1.39 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.38. | |
| Aytu BioScience has a poor financial position based on the latest SEC disclosures |
- Analyzing Aytu BioScience's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Aytu BioScience's stock is overvalued or undervalued compared to its peers.
- Examining Aytu BioScience's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Aytu BioScience's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Aytu BioScience's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Aytu BioScience's stock. These opinions can provide insight into Aytu BioScience's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Aytu Stock Analysis
When running Aytu BioScience's price analysis, check to measure Aytu BioScience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aytu BioScience is operating at the current time. Most of Aytu BioScience's value examination focuses on studying past and present price action to predict the probability of Aytu BioScience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aytu BioScience's price. Additionally, you may evaluate how the addition of Aytu BioScience to your portfolios can decrease your overall portfolio volatility.